Improving Nutrition for Babies Born by Caesarean Section
NCT ID: NCT07162025
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2025-09-30
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to develop an optimized infant formula. It includes: (1) isolation of probiotics from breast milk from nursing mothers and stool samples from their babies born vaginally, (2) formulation of an improved milk enriched with physiological lipids and selected probiotics, and (3) preclinical evaluation of its beneficial effects in a cesarean birth model.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Feeding After A Cesarean Delivery Hastens Recovery Time for Bowel Function
NCT02396485
Additional Effect of Wound Infiltration After Cesarean Section With Optimal Standard Analgesia
NCT01751256
Missing Microbes in Infants Born by Cesarean Section
NCT04134819
Early Oral Feeding Versus Traditional Postoperative Care After Cesarean Section.
NCT02332278
Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery
NCT01755026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Modern obstetric practices, while highly effective in reducing birth complications, have resulted in a high prevalence of cesarean deliveries. Several strategies have been explored to restore the microbiota of cesarean-born infants, including maternal vaginal or fecal microbiota transfer, but these approaches raise significant safety concerns. Breastfeeding has been shown to partially restore the gut microbiota of cesarean-born infants; however, breastfeeding rates are lower after cesarean section than after vaginal delivery, largely due to postnatal complications that interfere with breastfeeding initiation. Although specific infant formulas already exist for certain populations, none are currently designed to address the impaired primary colonization observed in cesarean-born infants.
The SPECIFI-C project has been designed to fill this gap by developing an innovative infant formula tailored to the specific needs of this population. The strategy focuses on two main components: (i) optimization of the microbiological fraction through supplementation with beneficial microorganisms isolated from human breast milk and infant feces, and (ii) optimization of the lipid fraction by incorporating bioactive lipids such as docosahexaenoic acid (DHA) and alkylglycerols, which are naturally present in breast milk but absent from current formulas.
The ultimate objective is to provide a safe and effective nutritional intervention that promotes healthy gut colonization and supports immune and physiological development in cesarean-born infants. By targeting a population that represents approximately 20% of births in France, the project aims to contribute to more precise and personalized nutrition strategies, with the potential to reduce both short- and long-term health risks associated with cesarean delivery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Aged 18 years and older Breastfeeding for less than 6 months Not having taken probiotics in the 6 months prior to sampling Not having taken antibiotics in the 6 months prior to sampling No chronic medical conditions Not undergoing chronic treatment No history of gestational diabetes Body mass index (BMI) below 25 at the start of pregnancy Having given their consent to participate in the study and to the collection of their baby's stool samples Not deprived of liberty or placed under guardianship
* Receiving medical supplementation other than conventional vitamins
Exclusion Criteria
* Under the age of 18
* Breastfeeding for 6 months or more
* Having been on antibiotic therapy in the 6 months prior to sampling
* Having taken probiotics in the 6 months prior to sampling
* Having a chronic illness
* Undergoing chronic treatment
* Who have developed gestational diabetes
* Who have a BMI greater than 25 at the start of pregnancy
* Who have given their consent to participate in the study (breast milk collection) but not to the collection of their baby's stool samples
* Who are deprived of their liberty or under guardianship.
Babies:
* Aged over 6 months
* Born by caesarean section
* Born before 37 weeks of pregnancy
* Not exclusively breastfed
* Having undergone intrapartum antibiotic treatment
* Taking medical supplements other than conventional vitamins
* Presenting with any type of pathology
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INRAE
Jouy-en-Josas, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A00676-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.